IL17A and psoriasis: Antagonizing this pro-inflammatory pathway by antibodies directed against the involved cytokines such as IL-17A and IL-23 or their receptors have demonstrated clinical efficacy in psoriasis, psoriatic arthritis, autoimmune uveitis, ankylosing spondylitis and Crohn`s disease [10–13].